Memorial Sloan Kettering Cancer Center shared a post on LinkedIn:
“A new drug is showing promise in lung and pancreatic cancers (two of the most aggressive forms of cancer) by targeting one of the most common cancer-driving mutations.
Researchers at Memorial Sloan Kettering Cancer Center (MSK), including gastrointestinal medical oncologist Dr. Wungki Park who led the global phase 1 clinical trial, shared results published in the New England Journal of Medicine.
The trial tested setidegrasib, a drug that tags and destroys the cancer-causing protein produced by the KRAS G12D mutation. This new method for targeting a long-known mutation is called a KRAS degrader.
KRAS mutations are present in about 1 in 5 cancers. The G12D subtype drives about 40% of pancreatic cancers and 5% of non-small cell lung cancers.
This drug’s potential is exciting, because the trial results suggest that setidegrasib can not only extend life for some patients with these aggressive cancers, it also has a very good safety profile, meaning the drug was well-tolerated with side effects that can be managed quite easily.
-says Dr. Park.
Learn more about this research.”
Other articles about Lung Cancer on OncoDaily.